Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
True North Therapeutics
company
About
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Clinical Trials,Health Care
- Founded date
- Jan 1, 2013
- Number Of Employee
- 11 - 50
- Operating Status
- Active
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$40M
True North Therapeutics has raised a total of
$40M
in funding over 2 rounds. Their latest funding was raised on
Dec 3, 2015 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 3, 2015 | Series C | $40M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
True North Therapeutics is funded by 1 investors.
Cowen Investment Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
